Table 3 Summary statistics for p.Val37Ile

From: Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen Hearing Loss Expert Panel

Alla

Casesb

Populationc

Counsyl

OR

95% CI

Z

P value

Total number of individuals tested for GJB2

17,635

802,339

654,426

    

Total number of alleles tested for GJB2

35,270

1,604,678

1,308,852

    

Total number of individuals with p.Val37Ile

464

10,233

7609

    

Total number of p.Val37Ile heterozygotes

313

9887

7370

    

Total number of p.Val37Ile homozygotes

151

346

239

20

17–24

31

<0.0001

Total number of p.Val37Ile compound heterozygotesd

115

N/Ae

96

    

Total number of p.Val37Ile alleles

615

10,488

7848

    

Overall p.Val37Ile allele frequency

0.0174

0.0065

0.0060

    

Number of Asian individuals tested for GJB2

2066

75,857

60,355

    

Number of Asian alleles tested for GJB2

4132

151,714

120,710

    

Number of Asian individuals with p.Val37Ile

197

6173

4023

    

Number of Asian p.Val37Ile heterozygotes

113

5898

3852

    

Number of Asian p.Val37Ile homozygotes

84

275

171

12

9.1–15

19

<0.0001

Number of Asian p.Val37Ile compound heterozygotesd with another GJB2 pathogenic allele

49

N/Ae

46f

19f

15–24f

26f

<0.0001f

Number of Asian p.Val37Ile alleles

281

6360

4194

1.7

1.5–1.9

8.1

<0.0001

p.Val37Ile allele frequency in Asians

0.0680

0.0419

0.0347

    
  1. CI confidence interval, OR odds ratio.
  2. Bold values indicate odds ratio exceeding 5 to meet PS4, as specified by the HL ClinGen group.
  3. aOnly probands (unrelated individuals) were counted. However, we could not rule out the possibility of related cases from different sites because cases were de-identified before being shared. Nevertheless, the likelihood of such occurrence would be low and would not significantly impact the conclusion.
  4. bThe total number of cases included in statistical analyses did not include BCH, DY, and GDWC where the total number of individuals tested at these sites were not available.
  5. cThe total population data were from Counsyl, CUHK, TAU, UNC, and gnomAD.
  6. dCompound heterozygosity was presumed in individuals with a second pathogenic or likely pathogenic variant in GJB2 that had never been reported to have occurred in cis.
  7. eNA: Not available, because individual allele state information is not available from gnomAD.
  8. fAnalyses involving compound heterozygotes were performed using Counsyl data as the population control (see “Materials and Methods”).